Ogawa Miho, Yokoyama Kazuaki, Imoto Seiya, Tojo Arinobu
Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Cancers (Basel). 2021 Apr 25;13(9):2078. doi: 10.3390/cancers13092078.
With the recent advances in noninvasive approaches for cancer diagnosis and surveillance, the term "liquid biopsy" has become more familiar to clinicians, including hematologists. Liquid biopsy provides a variety of clinically useful genetic data. In this era of personalized medicine, genetic information is critical to early diagnosis, aiding risk stratification, directing therapeutic options, and monitoring disease relapse. The validity of circulating tumor DNA (ctDNA)-mediated liquid biopsies has received increasing attention. This review summarizes the current knowledge of liquid biopsy ctDNA in hematological malignancies, focusing on the feasibility, limitations, and key areas of clinical application. We also highlight recent advances in the minimal residual disease monitoring of leukemia using ctDNA. This article will be useful to those involved in the clinical practice of hematopoietic oncology.
随着癌症诊断和监测的非侵入性方法的最新进展，“液体活检”一词已为包括血液科医生在内的临床医生所熟知。液体活检提供了各种临床上有用的基因数据。在这个个性化医疗的时代，基因信息对于早期诊断、辅助风险分层、指导治疗选择以及监测疾病复发至关重要。循环肿瘤DNA（ctDNA）介导的液体活检的有效性受到了越来越多的关注。本综述总结了血液系统恶性肿瘤中液体活检ctDNA的当前知识，重点关注其可行性、局限性和临床应用的关键领域。我们还强调了使用ctDNA监测白血病微小残留病的最新进展。本文将对参与造血肿瘤临床实践的人员有所帮助。
